Welcome back to another edition of the research roundup, where we discuss an eclectic collection of articles selected through the rigorous process of whatever I happened to find most interesting in my recent reading (with a couple suggestions from Dr. Casey Parker). The BroomeDocs podcast version can be found here: […]
Levetiracetam
6 posts
A true rarity: An RCT demonstrating a mortality benefit, but is it too good to be true? Matchett G, Gasanova I, Riccio CA, Nasir D, Sunna MC, Bravenec BJ, Azizad O, Farrell B, Minhajuddin A, Stewart JW, Liang LW, Moon TS, Fox PE, Ebeling CG, Smith MN, Trousdale D, Ogunnaike […]
I first heard about this article on Scott Weingart’s RACC Lit review, where he discussed it as a practice changing paper. In that context, I was excited to read it. I downloaded it as soon as I got out of the car. I will admit, I was pretty biased at […]
In the classic algorithm for status epilepticus, we give 2 doses of a benzodiazepine followed by phenytoin. Since the introduction of levetiracetam, we have seen a lot of strong opinions about the best second line agent, but we never had much data. (I have argued that we actually need to […]
Here is another collection of the articles I have found interesting in my reading from the last month or so. For this edition of the Research Roundup we have status epilepticus, nocebos, the pink lady, McGyver bias, and so much more. Podcast version over on BroomeDocs.
Status epilepticus is associated with a high degree of morbidity and mortality. Approximately ⅓ of patients have long term neurologic sequela, and mortality is 3-5%. (Chin 2006; Raspall-Chaure 2006) First line treatment is with benzodiazepines, but benzos will fail approximately 30-40% of the time. (Appleton 2008) Therefore, an effective second […]